RNA Virus Target Sequences for Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies face challenges in developing effective vaccines and treatments for RNA viruses, such as COVID-19, due to their high mutation rates and lack of understanding of their pathogenic mechanisms, leading to difficulties in determining virus virulence and susceptible populations.
Innovation Solution
Identification of conserved human insert sequences (HIS) in RNA viruses like SARS-CoV-2, which are used to develop target sequences for interacting with the human genome, enabling diagnosis, drug development, and vaccine optimization by activating inflammatory factors and increasing hyaluronic acid production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If vaccines are developed based on stable nucleotides sequence or proteins of viruses, then vaccine stability is improved, but effectiveness against RNA viruses is worsened due to high mutation rates
Solution Approach 1:
The patent extracts conserved regions from variable viral sequences and human insert sequences (HIS) from the viral genome that show high similarity to human DNA. By focusing on these conserved, stable regions rather than the entire variable genome, the invention creates vaccines that maintain stability while remaining effective against mutations.
Solution Approach 2:
The invention applies local quality by identifying specific conserved regions within the viral genome that maintain stability despite overall genomic mutation. These local conserved regions, particularly the HIS sequences with ≥95% similarity to human genome, are selected as vaccine targets to provide stable yet effective immunity.
2Measurement precision
If target sequences with high similarity to human genome are used, then interaction effectiveness is improved, but difficulty in distinguishing viral from human sequences is worsened
Solution Approach 1:
The patent uses human insert sequences (HIS) as intermediaries - these are viral sequences that naturally resemble human DNA. By targeting these intermediary sequences that bridge viral and human characteristics, the invention achieves effective viral-human interaction while the sequences remain distinguishable through their specific conserved patterns and locations within the viral genome.
Solution Approach 2:
The HIS sequences serve multiple functions: they are viral in origin (targeting coronavirus), yet resemble human sequences (enabling effective interaction), and maintain high conservation (providing stable targets). This multi-functionality resolves the contradiction between interaction effectiveness and sequence differentiation.
3Duration of action of stationary object
If conserved regions are targeted for vaccine development, then vaccine durability is improved, but adaptability to different virus strains is worsened
Solution Approach 1:
The patent performs preliminary identification and characterization of conserved regions and HIS sequences across multiple coronavirus strains before vaccine development. By pre-selecting targets that demonstrate conservation across strains, the invention ensures both durability against the primary strain and adaptability to emerging variants.
Solution Approach 2:
The invention changes the selection parameter from targeting highly variable regions to targeting conserved regions with specific similarity thresholds (≥95% to human genome). This parameter change enables the vaccine to maintain durability through conservation while achieving adaptability by selecting regions that are essential for viral function across different strains.
Data Source
AI summary
The present invention provides a target sequence of an RNA virus. The target sequence is a nucleic acid sequence fragment in the gene sequence in the RNA virus containing 20-40 bases and having not less than 95% similarity to genome sequence of human or related species such as livestock and poultry. The above-mentioned target sequence of the RNA virus is selected from SEQ ID NO. 1-SEQ ID NO. 615. The present invention also relates to a primer composition for constructing the above-mentioned target sequence, biomaterials such as antisense RNA related to the above-mentioned target sequence, and related uses such as design of a vaccine lacking the target sequence. The virus fragment with the above-mentioned sequence constructed in the present invention has the function of interacting with human genomic DNA and is similar to viral miRNA. Moreover, the effect of overexpression of the target sequence of the RNA virus on the expression level of surrounding genes is verified, and a new concept that the above-mentioned target fragment is an important pathogenic substance of the RNA virus is proposed. The above-mentioned target sequence has important application value for the detection and diagnosis of RNA viruses, drug screening, as well as the treatment of diseases caused by RNA viruses and the design/optimization of vaccines and methods.